Q-omics provides the consensus-scored CYP2U1-AS1 profile across patient tissues and cancer cell-line models. CYP2U1-AS1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CYP2U1-AS1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, CYP2U1-AS1 RNA expression shows 14,582 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where CYP2U1-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2U1-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2U1-AS1 survival associations across molecular data types. CYP2U1-AS1 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2U1-AS1 RNA expression–survival associations across cancer types. High CYP2U1-AS1 expression shows unfavorable associations in HNSC, ESCA, UCEC and LAML, but favorable associations in UVM and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CYP2U1-AS1 RNA expression.
This table summarizes CYP2U1-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2U1-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2U1-AS1 shows lower tumor expression in COAD, LUSC, BRCA, LIHC, HNSC and KIRC. The COAD box plot shows higher CYP2U1-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p < 0.001).
This table shows molecular features associated with CYP2U1-AS1 in patient tissues and cancer cell lines. In patient samples, CYP2U1-AS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
